6293-09-0

Usage

Uses

Used in Pharmaceutical Industry:
5,6-Dihydro-1H-imidazo[4,5-d]pyridazine-4,7-dione is used as a therapeutic agent for its potential medicinal properties. Its heterocyclic structure and the presence of nitrogen and oxygen atoms in the ring contribute to its potential as a pharmaceutical candidate.
Used in Chemical Synthesis:
5,6-Dihydro-1H-imidazo[4,5-d]pyridazine-4,7-dione is utilized in the synthesis of other organic compounds. Its unique chemical structure allows it to serve as a building block or intermediate in the creation of various chemical products, expanding its applications in the chemical industry.

InChI:InChI=1/C5H4N4O2/c10-4-2-3(7-1-6-2)5(11)9-8-4/h1-3H,(H,6,7)

Upstream product

• 1080-79-1 imidazole 4,5-dicarboxylic acid diethyl ester 
• 5423-20-1 1H-imidazole-4,5-dicarboxylic acid dihydrazide 
• 3304-70-9 dimethyl imidazole-4,5-dicarboxylate 

Downstream Products

• 1057681-55-6 7-benzyl-4-[4-(5-trifluoromethylpyridin-2-yl)piperazin-1-yl]-1H-imidazo[4,5-d]pyridazine 
• 100114-30-5 7-methylsulfanyl-1,5-dihydro-imidazo[4,5-d]pyridazine-4-thione 
• 17998-43-5 4,7-dichloro-1H-imidazo[4,5-d]pyridazine 
• 5453-50-9 5,6-dihydro-1H-imidazo[4,5-d]pyridazine-4,7-dithione 
• 28683-00-3 7-chloro-1,5-dihydro-imidazo[4,5-d]pyridazin-4-one 

Relevant academic research and scientific papers

1-Amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity

Abnormal activation of the Hedgehog (Hh) signaling pathway has been linked to several types of human cancers, and the development of small-molecule inhibitors of this pathway represents a promising route toward novel anticancer therapeutics. A cell-based screen performed in our laboratories identified a new class of Hh pathway inhibitors, 1-amino-4-benzylphthalazines, that act via antagonism of the Smoothened receptor. A variety of analogues were synthesized and their structure-activity relationships determined. This optimization resulted in the discovery of high affinity Smoothened antagonists, one of which was further profiled in vivo. This compound displayed a good pharmacokinetic profile and also afforded tumor regression in a genetic mouse model of medulloblastoma.

ORGANIC COMPOUNDS AND THEIR USES

The present disclosure relates to compounds relating to the diagnosis and treatment of pathologies relating to the Hedgehog pathway, including but not limited to tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders; specifically relating to compounds of formula (I).